We would love to hear your thoughts about our site and services, please take our survey here.
2 trades on YGEN this morning.
I don't think there are losers bailing out that affect the price.
It's more torpor.
However there are shares available. I bought 190,000 at 4.8p. 100,000 was 4.775p. Not significant so perhaps there are plenty of shares available
So, someone in the background selling regardless of falls in price?
A month or so ago 100k sales were fairly regular.
This is only conjecture, what do folks think?
253 employees in FY report (my last previous) record about 280).
200 in July presentation.
YGEN FY
253 employees
Covid virtually down to zero.
1st Qtr normal business back to 20%+ growth rates.
12 new IONA systems installed in the last 6 months.
Decentralisation of NIPT in the US a significant change in the landscape.
An expensive time for the company but it looks as if it is coping.
Impatient investor sentiment won't change.
Fast skim says no balance sheet tank traps but the complexity of the business evolution means they would be beyond my divination anyway.
Opinion
Unchanged.
apad
BTW. I see ASOS, BOO and SOS as quite different stories. I used to think BOO and SOS were similar until I realised that the founders were predicting the styles and keeping stock. ASOS is just a shop.
The BOO brands are now extraordinarily impressive and it is only about 3 months revenue to buy the whole company! I can't say I have ever seen anything so puzzling before.
You may be right, but I think they are very design focussed and selling through the likes of NXT and JL as well as not having to cope internationally will be a protection from the current environment. Anyroadup, I have bet the farm on them. Gulp!
I looked at Missguided's offerings and couldn't really see a brand style. Just loads and loads of stuff for a particular age range. If I compare it with Sosandar, that I follow closely, there I see style identity and carefull fashion sensitivity.
Good to have your insider viewpoint ragtrade.
Can anyone help me with this?
I did not see a clear statement that they had dropped Illumina but there seems to be an issue between conventional NIPT through Illumina and Ranger.
The nub of the issue seems to be whether, say, Illumina, or someone else, develops a similar process. IP has no real value until it is protected and YGEN can't afford a fight.
LR is a deal maker, so I guess the measure of progress is Ranger Roll Out.
Yourgene Health on Linkedin.
"The Clarigene SARS-CoV-2 #COVID19 assay does not utilise amplification of the S gene where the majority of viral strain mutations of concern are clustering."
They are linking this to the Omicron mutation.
apad
Interesting issue on test and repeat and another nod to ragtrade's much appreciated expertise. I had bought the test and repeat story hook line and sinker from back in the day (my BOO net cost is 91p) When Sosandar's results came out it became clear that they were operating an inventory model since May and had benefitted hugely from the designer's confidence in their 'lines'. As usual, I guess, it's not a single process world.